Does dual promoter-controlled oncolytic adenovirus CG5757 have strong tumor selectivity and significant antitumor efficacy in preclinical models?
CG5757 has strong antitumor selectivity and potency. It has low toxicity and has great potential as a therapeutic agent for different types of cancers.
In ovine OA-induced lung injury, rhAPC dampens the increase in pulmonary artery pressure and counteracts the development of lung edema and the derangement of arterial oxygenation.